Collaboration will further boost its promising pipeline of cancer treating therapies
Group B streptococcus vaccine study will involve adult groups with and without underlying conditions
Efti’s targeting activation of antigen-presenting cells delivers an adaptive immunity to fight cancer
The Oxford-based biotech company has secured £13.2m to progress world’s vital treatment development
Product delivers epigenetic information from a single low-input DNA library without medical treatment
Notable first clearance for R21/Matrix-M malaria vaccine for use in a specific country
Decision will create opportunity for therapy to be used earlier in the treatment pathway
Partnership will develop technology to screen and diagnose Lyme disease and diabetes
The trial will monitor patients across Europe for 24 months as they are treated with tildrakizumab
